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Abstract
People screened for human immunodeﬁciency virus (HIV) using rapid diagnostic tests (RDTs) in Africa remain generally unaware of their status
for hepatitis B (HBV) and hepatitis C (HCV) infections. We evaluated a two-step screening strategy in Burkina Faso, using both HIV RDTs and
Dried Blood Spot (DBS) assays to conﬁrm an HIV-positive test, and to test for HBV and HCV infections. HIV counselling and point-of-care
testing were performed at a voluntary counselling and testing centre with HBV, HCV status and HIV conﬁrmation using DBS specimens, being
assessed at a central laboratory. Serological testing on plasma was used as the reference standard assay to control for the performance of DBS
assays. Nineteen out of 218 participants included in the study were positive for HIV using RDTs. A fourth-generation HIV ELISA and
immunoblot assays on DBS conﬁrmed HIV status. Twenty-four out of 25 participants infected with HBV were found positive for hepatitis B
surface antigen (HBsAg) using DBS. One sample with a low HBsAg concentration on plasma was not detected on DBS. Five participants tested
positive for HCV antibodies were conﬁrmed positive with an immunoblot assay using DBS specimens. Laboratory results were communicated
within 7 days to participants with no loss to follow up of participants between the ﬁrst and second post-test counselling sessions. In conclusion,
DBS collection during HIV point-of-care testing enables screening and conﬁrmation of HBV, HCV and HIV infections. Diagnosis using DBSmay
assist with implementation of national programmes for HBV, HCV and HIV screening and clinical care in middle- to low-income countries.
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Introduction
Diagnosis of human immunodeﬁciency virus (HIV) infection in
resource-limited settings has increased substantially in recent
years through implementation of voluntary counselling and
testing programmes [1,2], with particular reference to the use
of point-of-care testing. Hepatitis B (HBV) and C (HCV)
infections share common routes of transmission with HIV, but
because of underdeveloped laboratory facilities and geographic
inaccessibility, diagnosis of these infections remains problematic
for many sub-Saharan African populations. Consequently, most
individuals remain unaware of their HBV and HCV status until
advanced stages of the disease, such as liver cirrhosis or
hepatocellular carcinoma, become evident. In Burkina Faso, the
prevalence rates of HIV, HBV and HCV infections are estimated
at 1.0–1.5% [3], 12–18% and 2–7%, respectively [4–6].
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In Africa, rapid diagnostic tests (RDTs) are largely used for
HIV testing. These types of tests offer the opportunity to
screen for HIV, to provide counselling regarding the implica-
tions of infection or its absence and to communicate the
screening results during a single visit. RDTs can be performed
on capillary blood, which requires less staff training, is less
invasive and involves smaller blood volumes than venous blood
collection. However, screening strategies based on HIV RDTs
have some limitations: (i) poor sensitivity in early stages of HIV
infection [7], (ii) suboptimal positive predictive values in
low-incidence countries [8], (iii) double reactivity of HIV-1 and
HIV-2 in settings like West Africa where HIV-2 co-circulates,
and (iv) lack of screening for HBV and HCV infections. Dried
blood spot (DBS) collection represents a promising alternative
to decrease these limitations. Capillary blood collection on a
ﬁlter card can be performed with relative ease in parallel with
HIV rapid testing, and sent with minimal further processing,
apart from optimal storage, to a central laboratory for perfor-
mance of additional screening and conﬁrmatory assays. Several
studies have demonstrated the effective use of DBS in HIV
diagnosis and monitoring [9–13]. DBS have been evaluated in
developed countries for HBV [14] as well as for HCV screening.
We have previously demonstrated that DBS specimens are
useful for screening and conﬁrmation of HCV infection [15].
In this pilot study, we evaluated a screening strategy based
on DBS sampling in parallel with HIV point-of-care testing to
both conﬁrm HIV RDT-positive results and to establish the
HBV and HCV status for persons attending a voluntary
counselling and testing in Bobo-Dioulasso, Burkina Faso.
Materials and Methods
Study population and specimen collection
This cross-sectional survey was conducted in Bobo-Dioulasso
(the second largest city in Burkina Faso) among people
attending the “Centre d’Accueil de Depistage et d’Information
sur le SIDA” (CADI). During pre-test counselling sessions,
HBV and HCV testing were offered to all the CADI clients as
an addition to HIV screening. Participants providing written
informed consent were enrolled and screened for the three
infections. Fig. 1 describes the operational procedure for
enrolment in the study and testing. For each participant, paired
plasma and DBS were simultaneously collected. For DBS
preparation, whole blood was spotted (5 spots of 50 lL) on to
ﬁlter-paper cards (Whatman 903TM, Protein Saver Card;
Whatman GmbH, Dassel, Germany).
Results of HIV point-of-care testing were given during
post-test counselling sessions within 1 h. Participants were
invited to return to theCADI1 week later for results ofHBVand
HCV testing. Individuals who tested positive for HIV, HCV or
HBV infection were referred to a dedicated hospital centre for
care and support. Screening and conﬁrmatory assays performed
on plasma were used as the reference standard to establish
serological status for HIV, HBV and HCV obtained on DBS.
HIV screening at the voluntary counselling and testing centre
HIV screening was performed by social counselling workers at
the CADI in accordance with a standard procedure recom-
mended by the National Guidelines on HIV testing that used
two RDTs in a sequential algorithm. Samples were tested using
a ﬁrst RDT (Determine HIV1/2; Inverness Medical, Chiba,
Japan). Samples found to be reactive with this ﬁrst RDT were
further assessed by a second immunochromatographic assay as
conﬁrmation (SD Bioline HIV1/2 3.0; Standard Diagnostics
Inc, Yongin-Si, South Korea) and to discriminate between HIV
type 1, type 2 and type 1 + 2 infections.
HIV screening and conﬁrmation at the central laboratory
Dried blood spot and paired plasma samples from each
participant were tested at the Virology Laboratory of Centre
Muraz in Bobo-Dioulasso using the GenscreenTM ULTRA HIV
Ag-Ab (Bio-Rad, Marnes-La-Coquette, France) which is a
fourth-generation commercial enzyme immunoassay (EIA) for
simultaneous detection of HIV p24 antigen and HIV antibodies
(HIV Ag/Abs). The lower limit of detection for p24 Ag with this
assay is 0.65 IU/mL in serum or plasma. For DBS testing, a
punched disc of 6-mm diameter was eluted overnight into
300 lL phosphate-buffered saline (PBS) solution for HIV EIA
test. The assays were performed and interpreted according to
the manufacturer’s instructions.
The HIV ELISA-positive specimens were analysed using a
line immunoassay (Inno-LiaTM HIV I/II Score; Innogenetics N.V.,
Gent, Belgium) on an automated system (Auto-LiaTM, Innoge-
netics) to conﬁrm or not the presence of antibodies against
HIV and to differentiate between HIV-1, HIV-2 and HIV-1/2
infections. For DBS in this conﬁrmatory assay, a punched disc
of 6 mm was eluted overnight in 150 lL PBS.
HBV testing
Dried blood spot and paired plasma samples from each
participant were tested at the Central Laboratory using the
ETI-MAK-4 HBsAg EIA (DiaSorin S.p.A, Saluggia, Italy) for HBV
surface antigen (HBsAg) detection and the MonolisaTM
Anti-HBc PLUS (Bio-Rad) for anti-HBV core antibodies
(anti-HBc Abs) detection. For DBS testing, a punched disc of
6-mm diameter was eluted overnight into 300 lL PBS for each
HBsAg test and into 150 lL PBS for anti-HBc Abs testing.
The assays were performed and interpreted according to
the manufacturer’s instructions with slight modiﬁcations for
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DBS specimens. For anti-HBc Abs testing on DBS, the
microplate was saturated overnight with 200 lL of bovine
serum albumin 10% in each well of the microplate before
performing the test. The cut-off absorbance values were
calculated according to the following formula: (i) DBS HBsAg
cut-off value = MAPC/2 + 0.3 and (ii) DBS anti-HBc Abs
cut-off value = MANC/3 + 2 SD; where MAPC is the mean
absorbance of positive control, MANC is the mean absorbance
of negative control, and SD is the standard deviation.
From HBsAg-positive individuals exhibiting low signal to
cut-off ratio by ELISA test (OD <3), the concentration of
HBsAg in plasma was measured using an Architect HBsAg QT
assay (Abbott, Chicago, IL).
HCV testing and conﬁrmation
Dried blood spot and paired plasma samples from each
participant were tested at the central Laboratory using the
MonolisaTM HCV Ab-Ag ULTRA assay (Bio-Rad), which is a
commercial EIA method for detecting HCV antigen and
anti-HCV Abs. For DBS testing, a punched disc of 6-mm
diameter was eluted overnight into 300 lL of ready-for-use
conjugate 1 (provided by the kit manufacturer Bio-Rad). The
assays were performed and interpreted according to the
manufacturer’s instructions.
Plasma and DBS HCV ELISA-positive specimens were
further assessed by the Inno-LiaTM HCV Score assay (Innoge-
netics). For DBS in this HCV conﬁrmatory assay, a 6-mm
punched disc was eluted overnight in 150 lL PBS.
To conﬁrm HCV infection, all the plasma-positive speci-
mens by the ﬁrst ELISA were also tested using another HCV
EIA (COBAS Anti-HCV assay; Roche Diagnostics GmbH,
Mannheim, Germany) and referred for PCR (COBAS Ampli-
Prep/COBAS TaqMan, HCV Test; Roche Diagnostics) when
the immunoblot assay was inconclusive.
FIG. 1. Operational procedure for partici-
pant’s enrolment and testing in the study.
1Study protocol determined not to enrol indi-
viduals who did not consent to additional
investigation for human immunodeﬁciency virus
(HIV), hepatitis B virus (HBV) and hepatitis C
virus (HCV) infection. However, in this pilot
study, all the participants attending the Centre
d’Accueil de Depistage et d’Information sur le
SIDA during the study period have consented
to undergo additional investigations.
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Statistical analyses
Analyses were performed on STATA/SE 11.0 (Statcorp, College
Station, TX, USA). Descriptive statistics were computed as
means or proportions. Distributions of continuous variables
were plotted to assess normality and ﬁt to adequate mathe-
matical functions to obtain a normal distribution. We
compared mean optical densities (OD) of DBS versus plasma
using the non-parametric Wilcoxon rank sum test.
We calculated sensitivity, speciﬁcity, positive predictive value
and negative predictive value of DBS versus plasma for each of
the laboratory assays (HBsAg, anti-HBc, HCV and HIV assays)
as simple proportions and obtained their corresponding 95%
CIs. Agreement between DBS results and that of plasma was
assessed using a kappa coefﬁcient and its 95% CI was obtained.
Results
Characteristics of study participants
From 21 June to 1 July 2011, a total of 218 consecutive
individuals counselled and accepting to be tested for HIV in the
CADI, consented to be enrolled in the study. The mean age of
study participants was 29.8  11.0 years. Women repre-
sented 62.8% with a sex ratio (M/F) of 0.6.
Testing for HIV, HBV and HCV on plasma served as the
reference standard to establish the serological status of each
participant for HIV, HBV and HCV infections. Of 218 samples,
23 (10.6%) tested positive for HIV using the fourth-generation
HIV Ag-Ab ELISA. Four EIA-positive samples (1.8%) yielded
indeterminate results by immunoblotting assay (with only the
presence of a gp41 band) and were considered as negative
after assessment of p24 Ag, HIV Abs (using the Roche Cobas
HIV Combi PT assay) and HIV-RNA PCR (data not shown).
Twenty-ﬁve (11.5%) plasma samples were positive for HBsAg
and 140 (64.2%) were positive for anti-HBc Abs (Table 1).
Seven plasma samples were found to be positive for
anti-HCV Abs. Immunoblotting conﬁrmed the detection of
anti-HCV Abs in plasma in ﬁve cases but it was negative for
two plasma samples that had low HCV screening signal to
cut-off ratio (OD 0.800 and 0.972, respectively, compared with
the cut-off value established at 0.439). These two samples were
considered as HCV negative because HCV RNA detection and a
second HCV Abs EIA were negative. Two participants were
co-infected by HIV and HBV, and one by HBV and HCV.
HIV rapid testing
Nineteen of 218 participants (8.7%) tested positive for HIV
using the ﬁrst screening RDT (Determine HIV1/2) and all of
these were conﬁrmed to be positive by the second RDT (SD
Bioline HIV1/2 3.0). One of the HIV-positive participants was
positive for both HIV-1 and HIV-2 Abs using the latter RDT.
Use of DBS for HIV screening and immunoblot conﬁrmation
HIV testing on DBS specimens using GenscreenTM ULTRA HIV
Ag-Ab assay and immunoblotting conﬁrmed all the HIV
infections detected by RDTs. As illustrated in Fig. 2a, a clear
difference in ELISA results was observed between HIV-positive
and HIV-negative DBS samples (mean plus SD of the OD
3.443  0.430 and 0.131  0.030, respectively; p <0.0001).
Clearly visible bands were obtained by DBS immunoblotting
(Fig. 3a) and they were similar to plasma immunoblotting in
terms of intensity and the number of visible bands. Immuno-
blotting on both DBS and plasma for the one result found to be
dually positive for HIV-1 and HIV-2 by HIV RDT (SD Bioline),
could not be conﬁrmed because no staining was observed on
the HIV-2 bands (gp105 and gp36).
HCV screening and conﬁrmation on DBS
All positive plasma samples for HCV were positive by DBS
testing (ﬁve samples, 2.3%) and all HCV-negative samples were
also accurately classiﬁed by the DBS assay (213 samples,
97.3%) (Fig. 2b). Positive HCV status by DBS was conﬁrmed by
immunoblotting and was similar to plasma in terms of intensity
and number of visible bands (Fig. 3b).
TABLE 1. Hepatitis B surface antigen (HBsAg), anti-hepatitis B virus core (HBc) antibody, hepatitis C virus (HCV) and human
immunodeﬁciency virus (HIV) prevalence rates and performance of Dried Blood Spot (DBS) as compared with plasma for HBV,
HCV and HIV detection among patients attending voluntary counselling and testing clinics in Bobo-Dioulasso, Burkina Faso
Marker
Prevalencea Sensitivity Speciﬁcity PPV NPV Kappa
% 95% CI % 95% CI % 95% CI % 95% CI % 95% CI Coeff 95% CI
HBsAg 11.5 7.7–16.4 96.0 77.7–99.8 100.0 97.6–100.0 100.0 82.8–100.0 99.5 96.7–100.0 0.98 0.91–1.00
Anti-HBc 64.2 57.5–70.6 99.3 95.5–100.0 98.7 92.1–99.9 99.3 95.5–100.0 98.7 92.1–99.9 0.98 0.91–1.00
HCV 2.3 0.7–5.3 100.0 46.3–100.0 100.0 97.8–100.0 100.0 46.3–100.0 100.0 97.8–100.0 1.00 0.93–1.00
HIV 8.7 5.3–13.3 100.0 79.1–100.0 100.0 97.6–100.0 100.0 79.1–100.0 100.0 97.6–100.0 1.00 0.93–1.00
PPV, positive predictive value; NPV, negative predictive value.
aPrevalence was estimated using plasma results.
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Detection of HBV infection and anti-HBc status on DBS
Compared with plasma, 24/218 (11.0%) DBS samples were
appropriately classiﬁed as positive for HBsAg and 193/218
(88.5%) as negative. The signal to cut-off ratio was ≥3 in most
of the cases, except for three DBS samples (Fig. 2c). HBsAg
quantiﬁcation in plasma indicated that these three participants
had lowHBsAg concentrations (0.53, 2.58 and2.86 log10 IU/mL).
One sample found to be positive for HBsAg in plasma was
negative using DBS (OD 0.268 in DBS versus 1.406 in paired
plasma); however, the plasma HBsAg level was especially low in
this sample (0.59 log10 IU/mL, data not shown).
For anti-HBc Abs, 139 (63.8%) DBS and paired plasma samples
were positive and 77 (35.2%) were negative. Anti-HBc Abs were
detected in DBS samples for all HBsAg-positive participants.
However, 10th centiles of OD for anti-HBc Ab-positive samples
and 90th centiles of OD for anti-HBc Ab-negative samples
tended to overlap, allowing for the misclassiﬁcation of 9.2% (20/
218) of samples (Fig. 2d). One (0.5%) false-negative result (DBS
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FIG. 2. Dried blood spot (DBS) optical density (OD) distribution with human immunodeﬁciency virus (HIV) status (a), hepatitis C virus (HCV)
status (b), hepatitis B virus surface antigen (HBsAg) status (c) and anti-hepatitis B virus core (HBc) status (d). HIV, HCV, HBsAg and anti-HBc status
were determined by performing enzyme immunoassays and conﬁrmatory tests on plasma. For each box, the middle-line of the rectangle represents
the median of DBS OD, the bottom-line of the rectangle indicates the 25th centile (p25) of DBS OD and the top-line of the rectangle indicates the
75th centile (p75) of DBS OD. The threshold of each assay is represented by the dotted line. The threshold values were established as recommended
by the manufacturer for HIV, and HCV (0.207 and 0.439, respectively) and was adapted for HBsAg and anti-HBc testing (HBsAg cut-off value = mean
absorbance of positive control/2 + 0.3 = 0.825; anti-HBc cut-off value = the mean absorbance of negative control/3 + 2SD = 0.075).
ª2013 The Authors
Clinical Microbiology and Infection ª2013 European Society of Clinical Microbiology and Infectious Diseases, CMI, 19, E533–E541
CMI Kania et al. Combining HIV, HBV and HCV screening on DBS E537
OD = 0.072 versus 0.484 for plasma) and one (0.5%) false-
positive result (DBS OD = 0.652 versus 0.059 in plasma) were
observed (data not shown) when compared with the anti-HBc
Abs cut-off value estimated at 0.075 in DBS.
Cost and analytical performances of the DBS assays for HBV,
HCV and HIV testing
Sensitivity, speciﬁcity, positive predictive value, negative pre-
dictive value and kappa coefﬁcient of DBS assays in comparison
with plasma assays for HBsAg, anti-HBc, HCV and HIV
detection are summarized in Table 1. The cost of the
consumables for HIV, HCV and HBV combined testing based
on capillary blood collection onto ﬁlter-paper card, including
the HIV RDTs, HIV Ag-Ab assay, HBsAg assay, anti-HBc Abs
assay and anti-HCV Ab assay was estimated to be €12.00
(€1.24 for the lancet and ﬁlter-paper card, €1.56 for other
consumables, €1 for the HIV RDTs, €8.20 for reagents of the
four ELISAs with €4.48 for HCV ELISA reagent). The cost of
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FIG. 3. Conﬁrmation of anti-human immuno-
deﬁciency virus (HIV) antibodies (a) and
anti-hepatitis C virus (HCV) antibodies (b)
using recombinant immunoblotting on dried
blood spots (DBS) and plasma specimens. The
INNO-LIATM HIV I/II Score and INNO-LIATM
HCV Score were respectively used to compare
the antibody reactivity against HIV and HCV
proteins on plasma and DBS. Results from ﬁve
representative participants are shown for each
marker. PLA, plasma sample; DBS, dried
blood spot sample; HIV+, positive samples for
anti-HIV antibody detection by means of ELISA
and immunoblotting; HIVind, positive samples
for anti-HIV antibody detection by means of
ELISA and indeterminate by immunoblotting;
HIV–, negative samples for anti-HIV antibody
detection by means of ELISA; HCV+, positive
samples for anti-HCV antibody detection by
means of ELISA.
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HIV and HCV conﬁrmation tests by immunoblot was esti-
mated to be €30 each.
Loss to follow-up of participants between their ﬁrst and
second post-test counselling sessions
All 218 participants included in this study returned for follow
up at the CADI to receive results on their HCV and HBV
infection status, as well as counselling once a week after
enrolment.
Discussion
This ﬁeld study conducted in West Africa showed that DBS
specimens may be successfully used in a two-step strategy
based on simple algorithms and commercial assays to conﬁrm
HIV RDTs and to complete screening for HBV and HCV
infections.
Blood collection on DBS can be performed with relative
ease in parallel with HIV rapid testing using a ﬁnger-prick in
adults and older children or a heel-prick in neonates and
infants. In this study, DBS was used to conﬁrm HIV RDT
results using fourth-generation ELISAs and immunoblotting.
The positive predictive value of RDTs has recently been
estimated as 98.0% (96.4–99.1%) in settings with a low
prevalence of HIV [8]. Hence, in low-incidence countries such
as Burkina Faso, where HIV prevalence is estimated to be
between 1.0 and 1.5% [3], false-positive results constitute a
signiﬁcant proportion of the positive results found with HIV
screening tests. Previous studies performed in African
pregnant women using HIV RDTs reported that >1% of the
results were indeterminate [16,17]. Spiking venous blood onto
DBS ﬁlter cards to perform conﬁrmatory tests may be
especially interesting in such cases.
In countries where HIV-2 infection is prevalent, positive
samples should be tested by conﬁrmatory assays that are able
to differentiate HIV-1 from HIV-2 Abs [18]. In our study one
participant tested positive for both HIV-1 and HIV-2 Abs by
the SD Bioline assay. This result remained unconﬁrmed by the
immunoblotting, suggesting a possible non-speciﬁc cross-reac-
tion with anti-HIV-1 Abs on the RDT. Immunoblotting using
assays such as the Inno-Lia HIV-1/HIV-2 assay may also provide
information on recent infection (up to three bands), or on
advanced disease (loss of the p24 Ag). When comparing paired
bands obtained from DBS and plasma, results showed a good
concordance. This supports the use of DBS in reference
laboratories for quality control of HIV results obtained by
point-of-care testing performed in voluntary counselling and
testing centres, and for the discrimination between HIV-1 and
HIV-2 infections before the initiation of antiretroviral therapy.
HIV diagnostic strategies including fourth-generation ELISA
combining HIV Ag/Abs detection on DBS [19] may also
improve the diagnosis of primary HIV infection. Evidence
supports the fact that primary HIV infection is indeed
frequently missed during the seroconversion phase by the
HIV RDTs [20] even when using a p24/Abs combined RDT [7].
The prevalence rate of HIV in our study is similar to those
observed in 2010 and 2011 in the CADI (8.5% and 6.5%,
respectively, personal data). However, it is not representative
of the estimated nationwide prevalence in Burkina Faso
(around 1%) [3], suggesting that participants undergoing
voluntary counselling and testing tend to be at higher risk
for HIV infection.
Using commercial EIA tests, our study shows that assays on
DBS were able to successfully detect HBsAg in HBV-infected
participants. As expected, the lower limit of detection of
antibodies and antigen is higher using DBS than plasma [21]
and one individual with low HBsAg concentration was found to
be negative for HBsAg on DBS but positive on plasma in this
study. Data on HBsAg concentrations in participants chron-
ically infected with HBV demonstrate that the level of HBsAg
below 100 IU/mL is unusual [22–24], suggesting that DBS may
be sufﬁcient for HBsAg detection in the vast majority of cases.
Overall, the ODs of DBS samples from participants reactive
for HIV, HCV Abs or HBsAg did not overlap with ODs of DBS
samples from negative individuals. In contrast, detection of
anti-HBc Abs was less obvious with the lowest ratio of the
anti-HBc Abs positive/negative OD. Villar et al. [21] recently
reported a relatively low sensitivity (90.5%) for anti-HBc
antibody detection using DBS. This may be partially explained
by the suboptimal intrinsic performance of competitive
immunoassays aimed to detect anti-HBc Abs [25]. Regarding
the population size in our study, the total number of positive
samples was low for HIV and HBV and least for HCV which
may impact on the accuracy of the assays’ performance
observed in our study. However, the good analytical perfor-
mance of DBS assays obtained in our study is similar to those
previously reported for HCV [15] and HBV [21,26] screening
using DBS.
Testing for HIV, HBV and HCV using DBS samples may not
necessarily be less expensive than classical serology, but in
developing countries DBS testing may be much more feasible
to perform compared with classical serology requiring
venous blood sampling, which requires infrastructural support
(electrical power, centrifuge, etc.), and storage and transpor-
tation requirements (cooling chain, ice box, dry ice, space
consumption, etc.). Besides voluntary counselling and testing
centres, our algorithm may be useful in antenatal clinics by
adding HBV and HCV screening to the HIV DNA or RNA
testing performed in newborns, and particularly useful for
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HBsAg screening in pregnant women to optimize the preven-
tion of mother-to-child transmission through early vaccination
of neonates.
The costs associated with antiviral therapy for chronic HBV
and HCV infections as well as the lack of laboratory facilities for
diagnosis and monitoring are some of the main limitations for
treatment of chronic viral hepatitis in resource-limited settings.
As a consequence, hepatocellular carcinoma is one of the three
most commonly described tumours in sub-Saharan Africa [27].
This survey conducted in ﬁeld conditions of a resource-
limited setting demonstrates the feasibility of screening and
conﬁrming HBV, HCV and HIV status using a two-step strategy
to combine RDTs plus DBS testing. Viral testing on DBS
presents a particular beneﬁt for many developing countries in
sub-Saharan Africa, like Burkina Faso, where environmental
and logistical conditions are not always favourable for the
timely transportation and storage of samples such as plasma or
serum that have to be obtained by venous puncture. The DBS
can be collected in remote rural areas, sent at room
temperature to a central reference laboratory, and results
communicated using mobile phone texting as recently reported
[28,29]. DBS diagnosis can also assist in evaluating the
implementation of a national programme for HBV and
HCV screening and care in middle-income and low-income
countries.
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